Aktienanalyse zu Decoy Therapeutics Inc (DCOY)DCOYDecoy Therapeutics Inc

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals. It operates in the Healthcare sector.

Decoy Therapeutics Inc (DCOY) is currently trading at $1.13, significantly down 88.79% year-to-date. The company has shown a recent positive trend with a 5-day change of +5.60%, but it remains a penny stock with high volatility. The RSI is at 50.649, indicating a neutral momentum. The forward P/E ratio is 0, reflecting uncertainty in future earnings. The gross margin has improved to 100% in the latest quarter, but the company reported a net loss of $2,373,800 in Q2 2026. The main risk is its substantial year-to-date decline of 88.79%, which raises concerns about its long-term viability. Given these factors, it may be prudent to hold rather than buy at this time.